SG164279A1 - Tricyclic thrombin receptor antagonists - Google Patents

Tricyclic thrombin receptor antagonists

Info

Publication number: SG164279A1
Authority: SG; Singapore
Prior art keywords: substituted; bond; receptor antagonists; optionally substituted; thrombin receptor
Prior art date: 2002-04-16

Application number

SG200607217-7A

Other languages

English (en)

Inventor

Samuel Chackalamannil

Martin C Clasby

William J Greenlee

Yuguang Wang

Yan Xia

Enrico P Veltri

Mariappan Chellian

Wenxue Wu

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2003-04-14

Publication date

2010-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG164279(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-14 Application filed by Schering Corp filed Critical Schering Corp

2010-09-29 Publication of SG164279A1 publication Critical patent/SG164279A1/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG200607217-7A 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists SG164279A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37307202P	2002-04-16	2002-04-16

Publications (1)

Publication Number	Publication Date
SG164279A1 true SG164279A1 (en)	2010-09-29

Family

ID=29250954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200607217-7A SG164279A1 (en)	2002-04-16	2003-04-14	Tricyclic thrombin receptor antagonists

Country Status (34)

Country	Link
US (3)	US7304078B2 (no)
EP (5)	EP1860106B1 (no)
JP (2)	JP4558331B2 (no)
KR (1)	KR101026929B1 (no)
CN (1)	CN1659162B (no)
AR (1)	AR039570A1 (no)
AT (3)	ATE378330T1 (no)
AU (1)	AU2003221932B2 (no)
BR (1)	BRPI0309309B8 (no)
CA (1)	CA2482858C (no)
CY (3)	CY1107184T1 (no)
DE (3)	DE60331114D1 (no)
DK (2)	DK2065384T3 (no)
EC (1)	ECSP045368A (no)
ES (3)	ES2357876T3 (no)
FR (1)	FR15C0047I2 (no)
HK (3)	HK1070887A1 (no)
IL (1)	IL164585A (no)
LT (1)	LTC1495018I2 (no)
LU (1)	LU92759I2 (no)
MX (1)	MXPA04010308A (no)
MY (1)	MY144040A (no)
NL (1)	NL300746I2 (no)
NO (2)	NO330500B1 (no)
NZ (2)	NZ575139A (no)
PE (1)	PE20040412A1 (no)
PL (1)	PL214718B1 (no)
PT (2)	PT2065384E (no)
RU (2)	RU2329264C9 (no)
SG (1)	SG164279A1 (no)
SI (2)	SI1495018T1 (no)
TW (1)	TWI343919B (no)
WO (1)	WO2003089428A1 (no)
ZA (1)	ZA200408342B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
ATE406366T1 (de) *	2004-05-28	2008-09-15	Schering Corp	Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
CA2582353A1 (en) *	2004-10-06	2006-04-20	University Of Rochester	Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
PL2206697T3 (pl) *	2005-01-14	2012-03-30	Merck Sharp & Dohme	Egzo- oraz diastereoselektywna synteza analogów himbacyny
US7541471B2 (en) *	2005-01-14	2009-06-02	Schering Corporation	Synthesis of himbacine analogs
US7772276B2 (en) *	2005-01-14	2010-08-10	Schering Corporation	Exo-selective synthesis of himbacine analogs
CN101137614A (zh) *	2005-01-14	2008-03-05	先灵公司	喜巴辛类似物的手性炔丙醇和酯中间体的制备
WO2006076564A1 (en) *	2005-01-14	2006-07-20	Schering Corporation	Synthesis of himbacine analogs
KR20070116066A (ko) *	2005-03-31	2007-12-06	쉐링 코포레이션	스피로사이클릭 트롬빈 수용체 길항제
WO2007075808A2 (en) *	2005-12-20	2007-07-05	Schering Corporation	Methods for preventing and/or treating a cell proliferative disorder
EP1971336A2 (en) *	2005-12-22	2008-09-24	Shering Corporation	Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery
PE20080183A1 (es) *	2006-04-06	2008-03-10	Schering Corp	Terapias de combinacion de tra
EP2266976B1 (en)	2006-04-13	2013-07-31	Merck Sharp & Dohme Corp.	Fused ring thrombin receptor antagonists
AR061664A1 (es) *	2006-06-29	2008-09-10	Schering Corp	Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
TWI367112B (en) *	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) *	2006-06-30	2008-09-17	Schering Corp	Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de)	2006-08-02	2008-02-07	Sanofi-Aventis	Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008060372A2 (en) *	2006-10-04	2008-05-22	Schering Corporation	Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
US8153664B2 (en)	2006-10-04	2012-04-10	Schering Corporation	Bicyclic and tricyclic derivatives as thrombin receptor antagonists
WO2008079260A2 (en) *	2006-12-22	2008-07-03	Schering Corporation	Disintegration promoters in solid dose wet granulation formulations
JP2010522169A (ja) *	2007-03-23	2010-07-01	シェーリングコーポレイション	トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減
MY152040A (en)	2008-02-05	2014-08-15	Sanofi Aventis	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
AU2009211888B2 (en)	2008-02-05	2013-06-20	Sanofi	Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) *	2008-04-02	2009-10-08	Schering Corporation	Combination therapies comprising par1 antagonists with par4 antagonists
EP2300435A2 (en)	2008-05-19	2011-03-30	Schering Corporation	Heterocyclic compounds as factor ixa inhibitors
WO2010141525A1 (en) *	2009-06-04	2010-12-09	Schering Corporation	Active metabolite of a thrombin receptor antagonist
EP2440191A2 (en)	2009-06-08	2012-04-18	Schering Corporation	A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011017296A1 (en)	2009-08-04	2011-02-10	Schering Corporation	4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2011128421A1 (de)	2010-04-16	2011-10-20	Sanofi	Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
ES2527535T3 (es)	2010-04-16	2015-01-26	Sanofi	Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko)	2010-06-25	2013-09-03	한국화학연구원	트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en)	2012-03-06	2016-05-17	Merck Sharp & Dohme Corp.	Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
EP3024550A4 (en) *	2013-07-22	2016-12-07	Merck Sharp & Dohme	CO-CRYSTAL OF VORAPAXAR PAR-1 RECEPTOR ANTAGONIST AND ASPIRINE
EP3035928B1 (en) *	2013-08-22	2023-10-18	Merck Sharp & Dohme LLC	3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026693A1 (en) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035930A4 (en) *	2013-08-22	2017-03-08	Merck Sharp & Dohme Corp.	7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr)	2013-12-16	2016-01-08	Pf Medicament	Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en)	2014-04-16	2018-05-15	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
CN105985303B (zh) *	2015-02-13	2020-08-14	上海彩迩文生化科技有限公司	抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) *	2015-09-01	2017-03-08	博瑞生物医药（苏州）股份有限公司	沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) *	2015-11-25	2017-05-31	博瑞生物医药（苏州）股份有限公司	一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) *	2016-02-05	2017-08-10	Sanovel Ilac Sanayi Ve Ticaret A.S.	A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) *	2016-02-05	2018-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
CN107304200B (zh) *	2016-04-22	2021-09-21	江苏天士力帝益药业有限公司	一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) *	2016-08-22	2016-12-21	孔五	一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr)	2018-12-19	2021-05-07	Cvasthera	Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) *	2019-08-02	2020-06-26	牡丹江医学院	一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) *	2019-10-21	2021-04-22	United States Government as Represented by the Department of Veteran Affairs	Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr)	2020-04-08	2023-04-14	Cvasthera	Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
JP2023534704A (ja)	2020-07-22	2023-08-10	ヤンセンファーマシューティカエヌ．ベー．	第ｘｉａ因子阻害剤として有用な化合物
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr)	2022-04-08	2023-10-13	Cvasthera	Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
WO2001096330A2 (en) *	2000-06-15	2001-12-20	Schering Corporation	Thrombin receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
PE133799A1 (es) *	1997-11-25	2000-01-10	Schering Corp	Antagonistas del receptor de trombina
FR2779726B1 (fr)	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en)	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US7488742B2 (en)	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
MXPA04003610A (es)	2001-10-18	2004-07-27	Schering Corp	Analogos de himbacina como antagonistas del receptor de trombina.

2003
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en active Application Filing
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko active IP Right Grant
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
2005
- 2005-04-22 HK HK05103479A patent/HK1070887A1/xx not_active IP Right Cessation
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
2009
- 2009-03-23 HK HK09102736.6A patent/HK1123302A1/xx not_active IP Right Cessation
- 2009-09-14 HK HK09108388.4A patent/HK1129893A1/xx not_active IP Right Cessation
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I2/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
WO2001096330A2 (en) *	2000-06-15	2001-12-20	Schering Corporation	Thrombin receptor antagonists

Also Published As

Publication number	Publication date
KR101026929B1 (ko)	2011-04-04
EP1982984B1 (en)	2013-02-13
PE20040412A1 (es)	2004-07-12
LU92759I2 (en)	2015-08-31
HK1123302A1 (en)	2009-06-12
NO330500B1 (no)	2011-05-02
DK2065384T3 (da)	2011-05-02
AU2003221932A1 (en)	2003-11-03
DE60317493T2 (de)	2008-09-18
ES2297150T3 (es)	2008-05-01
SI1495018T1 (sl)	2008-04-30
JP4558331B2 (ja)	2010-10-06
RU2004133375A (ru)	2005-07-10
US20070179187A1 (en)	2007-08-02
EP1982984A2 (en)	2008-10-22
JP2005528406A (ja)	2005-09-22
EP1495018B1 (en)	2007-11-14
CY1111363T1 (el)	2015-08-05
ZA200408342B (en)	2006-05-31
AU2003221932B2 (en)	2007-11-22
EP1982984A3 (en)	2008-10-29
NO20044963L (no)	2004-11-15
JP2010132710A (ja)	2010-06-17
CY1107184T1 (el)	2012-10-24
EP2062890B1 (en)	2011-01-05
BRPI0309309B8 (pt)	2021-05-25
DE60331114D1 (de)	2010-03-11
DK1495018T3 (da)	2008-02-18
HK1070887A1 (en)	2005-06-30
MY144040A (en)	2011-07-29
CA2482858A1 (en)	2003-10-30
ATE378330T1 (de)	2007-11-15
NO2015016I1 (no)	2015-07-20
MXPA04010308A (es)	2005-02-03
BRPI0309309B1 (pt)	2018-09-04
RU2329264C9 (ru)	2009-04-20
PL373332A1 (en)	2005-08-22
PL214718B1 (pl)	2013-09-30
DE60335679D1 (de)	2011-02-17
US7304078B2 (en)	2007-12-04
ES2357876T3 (es)	2011-05-03
AR039570A1 (es)	2005-02-23
EP1860106A1 (en)	2007-11-28
CY2015029I2 (el)	2016-04-13
EP2065384B1 (en)	2011-01-05
PT1495018E (pt)	2008-02-19
CA2482858C (en)	2010-11-30
EP2062890A1 (en)	2009-05-27
NL300746I1 (no)	2016-01-21
BR0309309A (pt)	2005-02-15
NL300746I2 (no)	2016-01-21
HK1129893A1 (en)	2009-12-11
CN1659162B (zh)	2011-08-31
WO2003089428A1 (en)	2003-10-30
FR15C0047I2 (fr)	2016-05-06
KR20040099441A (ko)	2004-11-26
CY2015029I1 (el)	2016-04-13
IL164585A (en)	2010-11-30
SI2065384T1 (sl)	2011-05-31
TWI343919B (en)	2011-06-21
ATE455774T1 (de)	2010-02-15
DE60317493T3 (de)	2018-07-12
NZ575139A (en)	2010-08-27
IL164585A0 (en)	2005-12-18
US20070270439A1 (en)	2007-11-22
RU2329264C2 (ru)	2008-07-20
ATE494284T1 (de)	2011-01-15
LTC1495018I2 (lt)	2017-04-10
US7713999B2 (en)	2010-05-11
DE60317493D1 (en)	2011-01-13
RU2008106401A (ru)	2009-08-27
ES2338171T3 (es)	2010-05-04
NO2015016I2 (no)	2015-07-09
EP1495018A1 (en)	2005-01-12
ES2297150T7 (es)	2012-03-16
EP1860106B1 (en)	2010-01-20
US20030216437A1 (en)	2003-11-20
FR15C0047I1 (no)	2015-08-28
TW200404068A (en)	2004-03-16
EP1495018B3 (en)	2011-03-16
CN1659162A (zh)	2005-08-24
EP2065384A1 (en)	2009-06-03
ECSP045368A (es)	2005-01-03
PT2065384E (pt)	2011-03-16
NZ535880A (en)	2007-11-30

Publication	Publication Date	Title
SG164279A1 (en)	2010-09-29	Tricyclic thrombin receptor antagonists
MX2009003761A (es)	2009-06-30	Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
TW200626584A (en)	2006-08-01	Thrombin receptor antagonists
WO2006105217A3 (en)	2006-11-23	Spirocyclic thrombin receptor antagonists
MY139335A (en)	2009-09-30	Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
EA200801909A1 (ru)	2009-06-30	Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
WO2007126771A3 (en)	2007-12-21	Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
NO20062239L (no)	2006-06-21	Nye tetrahydrospiro[piperidin-2,7'-pyrrolo[3,2-b]pyridinderivater og nye indolderivater nyttige i behandlingen av 5-HT6 reseptorrelaterte forstyrrelser
WO2007075809A3 (en)	2008-02-21	Oxazoloisoquinoline derivatives as thrombin receptor antagonists
GB9914486D0 (en)	1999-08-18	Medicaments
PE20041076A1 (es)	2005-01-22	Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
WO2007046867A3 (en)	2007-07-05	Piperidine derivatives and their uses as therapeutic agents
TW200635897A (en)	2006-10-16	Piperidine derivatives and their use as anti-inflammatory agents
WO2006044362A3 (en)	2006-12-07	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2007044085A3 (en)	2007-06-28	Heteroaryl compounds and their uses as therapeutic agents
WO2007044804A3 (en)	2009-05-07	Piperidine derivatives and methods of use
BRPI0418939A (pt)	2008-04-08	derivados de nicotinamida e sua utilização como agentes terapêuticos
MX2007006387A (es)	2007-06-20	Derivados de piridina 3-substituidos como antagonistas h3.
MX2009003758A (es)	2009-04-22	Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
EA200901572A1 (ru)	2010-04-30	3-(имидазолил)пиразоло[3,4-b]пиридины
MY140887A (en)	2010-01-29	Thrombin receptor antagonists
WO2006125194A3 (en)	2007-01-04	Piperazine derivatives and their uses as therapeutic agents
TW200732304A (en)	2007-09-01	Piperidine derivatives
WO1999026932A8 (en)	1999-09-10	By amidino group substituted heterocyclic derivatives and their use as anticoagulants
GEP20115216B (en)	2011-05-25	New phenanthridine derivatives as bradykinin antagonists